- Home
- EYPT
as 06-03-2025 4:00pm EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 390.0M | IPO Year: | 2005 |
| Target Price: | $24.29 | AVG Volume (30 days): | 896.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $13.98 | Next Earning Date: | 05-07-2025 |
| Revenue: | $56,042,000 | Revenue Growth: | 12.04% |
| Revenue Growth (this year): | -31.1% | Revenue Growth (next year): | -52.98% |
Stock Insider Trading Activity of EyePoint Pharmaceuticals Inc. (EYPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zaderej Karen L. | EYPT | Director | May 16 '25 | Buy | $5.90 | 10,000 | $59,000.00 | 31,500 | |
| Zaderej Karen L. | EYPT | Director | May 14 '25 | Buy | $5.45 | 10,000 | $54,450.00 | 31,500 |
Latest EyePoint Pharmaceuticals Inc. News
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
8 days ago
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
MT Newswires
19 days ago
Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating
GlobeNewswire
19 days ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
EyePoint Announces Participation at Upcoming Investor Conferences
Simply Wall St.
24 days ago
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Simply Wall St.
25 days ago
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Zacks
a month ago
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
Compare EYPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.